GlassScriptPhysician profile
Shelby True
NPI 1124745112
$2,488.01
in general payments reported to CMS, 2019-2025
27 companies · $949 in 2025
The $949 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $146 · 2023: $583 · 2024: $811 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,248 · Education: $94.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.50 |
| Education | $94.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.99 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $243.16 | 2025 | Fanapt |
| Novo Nordisk INC | $236.12 | 2022-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.29 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $143.41 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Gilead Sciences, INC. | $113.57 | 2023-2025 | |
| Corium, LLC | $108.26 | 2022-2025 | Azstarys |
| Indivior INC. | $95.34 | 2024-2025 | Sublocade |
| Glaxosmithkline, LLC. | $94.18 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Axsome Therapeutics, INC. | $92.96 | 2023-2024 | Auvelity |
| Lilly USA, LLC | $81.75 | 2023-2024 | Mounjaro, Zepbound, Lyumjev |
| Bayer Healthcare Pharmaceuticals INC. | $78.83 | 2022-2023 | |
| Pfizer INC. | $75.22 | 2024-2025 | |
| Lundbeck LLC | $52.68 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $49.65 | 2022-2024 | Ingrezza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.69 | 2022-2023 | |
| Mannkind Corporation | $39.25 | 2023 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $28.66 | 2024 | Farxiga, Airsupra |
| Exact Sciences Corporation | $28.31 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $24.08 | 2025 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $14.23 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $13.71 | 2022 | |
| Sanofi Pasteur INC. | $13.37 | 2023 | |
| Hologic Sales and Service, LLC | $13.33 | 2023 | Aptima |
| Janssen Pharmaceuticals, INC | $13.20 | 2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $12.52 | 2022 | |
| Phathom Pharmaceuticals, INC. | $8.25 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelby True listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.